Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426447 | 0.86 | CXCR4 (0.41) | CXCR4BCHE | |
| SCHEMBL2202937 | 0.83 | CXCR4 (0.38) | CXCR4 | |
| SCHEMBL2202949 | 0.83 | CXCR4 (0.38) | CXCR4 | |
| SCHEMBL2201743 | 0.82 | CXCR4 (0.39) | CXCR4TSHRBCHEHRH3 | |
| SCHEMBL2203825 | 0.80 | TSHR (0.44) | TSHRBCHE | |
| SCHEMBL2201359 | 0.78 | CXCR4 (0.47) | CXCR4TSHRLMNAPKMNPSR1 | |
| SCHEMBL2200325 | 0.78 | MAOA (0.40) | TSHRBCHE | |
| SCHEMBL12426446 | 0.76 | CXCR4 (0.43) | CXCR4LMNAHRH3 | |
| SCHEMBL2202941 | 0.73 | CXCR4 (0.39) | CXCR4TSHRBCHEHRH3 | |
| SCHEMBL2205031 | 0.73 | ALDH1A1 (0.41) | TSHRLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | CXCR4 2546/4885TSHR 2682/4885LMNA 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.